|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size 8/07/18 Opko Health, Inc. 10-Q 6/30/18 77:9.3M |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 708K
2: EX-10.1 Material Contract HTML 52K
3: EX-31.1 Certification -- §302 - SOA'02 HTML 29K
4: EX-31.2 Certification -- §302 - SOA'02 HTML 29K
5: EX-32.1 Certification -- §906 - SOA'02 HTML 23K
6: EX-32.2 Certification -- §906 - SOA'02 HTML 23K
13: R1 Document and Entity Information HTML 41K
14: R2 Condensed Consolidated Balance Sheets HTML 111K
15: R3 Condensed Consolidated Balance Sheets HTML 32K
(Parenthetical)
16: R4 Condensed Consolidated Statements of Operations HTML 104K
17: R5 Condensed Consolidated Statements of Comprehensive HTML 48K
Loss
18: R6 Condensed Consolidated Statements of Cash Flows HTML 134K
19: R7 Business and Organization HTML 28K
20: R8 Summary of Significant Accounting Policies HTML 117K
21: R9 Earnings (Loss) Per Share HTML 79K
22: R10 Composition of Certain Financial Statement HTML 123K
Captions
23: R11 Acquisitions, Investments and Licenses HTML 52K
24: R12 Debt HTML 110K
25: R13 Accumulated Other Comprehensive Income (Loss) HTML 39K
26: R14 Fair Value Measurements HTML 92K
27: R15 Derivative Contracts HTML 53K
28: R16 Related Party Transactions HTML 33K
29: R17 Commitments and Contingencies HTML 35K
30: R18 Revenue Recognition HTML 91K
31: R19 Strategic Alliances HTML 48K
32: R20 Segments HTML 155K
33: R21 Subsequent Events HTML 24K
34: R22 Summary of Significant Accounting Policies HTML 186K
(Policies)
35: R23 Summary of Significant Accounting Policies HTML 68K
(Tables)
36: R24 Earnings (Loss) Per Share (Tables) HTML 73K
37: R25 Composition of Certain Financial Statement HTML 125K
Captions (Tables)
38: R26 Acquisitions, Investments and Licenses (Tables) HTML 44K
39: R27 Debt (Tables) HTML 90K
40: R28 Accumulated Other Comprehensive Income (Loss) HTML 39K
(Tables)
41: R29 Fair Value Measurements (Tables) HTML 87K
42: R30 Derivative Contracts (Tables) HTML 54K
43: R31 Revenue Recognition (Tables) HTML 69K
44: R32 Segments (Tables) HTML 152K
45: R33 Business and Organization (Details) HTML 23K
46: R34 Summary of Significant Accounting Policies HTML 117K
(Details)
47: R35 Summary of Significant Accounting Policies - HTML 81K
Schedule of Topic 606 Impact (Details)
48: R36 Earnings (Loss) Per Share - Schedule of Earnings HTML 61K
(Loss) Per Share, Basic and Diluted (Details)
49: R37 Earnings (Loss) Per Share - Narrative (Details) HTML 33K
50: R38 Composition of Certain Financial Statement HTML 143K
Captions (Details)
51: R39 Composition of Certain Financial Statement HTML 57K
Captions - Changes in Goodwill (Details)
52: R40 Acquisitions, Investments and Licenses - Summary HTML 36K
of Investments (Details)
53: R41 Acquisitions, Investments and Licenses - Equity HTML 56K
and Cost Method Investments Narrative (Details)
54: R42 Acquisitions, Investments and Licenses - Available HTML 48K
for Sale Investments, Sale of Investments and
Warrants and Options Narrative (Details)
55: R43 Acquisitions, Investments and Licenses - Schedule HTML 28K
of Net Gains and Losses on Equity Securities
(Details)
56: R44 Acquisitions, Investments and Licenses - Variable HTML 34K
Interest Entities Narrative (Details)
57: R45 Debt - Narrative (Details) HTML 160K
58: R46 Debt - Notes (Details) HTML 47K
59: R47 Debt - Lines Of Credit (Details) HTML 61K
60: R48 Debt - Mortgage Notes And Other Debt (Details) HTML 32K
61: R49 Accumulated Other Comprehensive Income (Loss) HTML 47K
(Details)
62: R50 Fair Value Measurements - Assets And Liabilities HTML 74K
Measured At Fair Value (Details)
63: R51 Fair Value Measurements - Level 3 Reconciliation HTML 29K
(Details)
64: R52 Fair Value Measurements - Narrative (Details) HTML 34K
65: R53 Derivative Contracts - Balance Sheet Component HTML 37K
(Details)
66: R54 Derivative Contracts - Derivative Gains (Losses) HTML 33K
(Details)
67: R55 Related Party Transactions (Details) HTML 141K
68: R56 Commitments and Contingencies (Details) HTML 44K
69: R57 Revenue Recognition - Schedule of Disaggregation HTML 37K
of Revenue (Details)
70: R58 Revenue Recognition - Narrative (Details) HTML 42K
71: R59 Revenue Recognition - Schedule of Product Sales HTML 50K
Allowances and Accruals (Details)
72: R60 Strategic Alliances (Details) HTML 118K
73: R61 Segments - Narrative (Details) HTML 48K
74: R62 Segments - Operations and Assets Information HTML 87K
(Details)
76: XML IDEA XML File -- Filing Summary XML 136K
75: EXCEL IDEA Workbook of Financial Reports XLSX 109K
7: EX-101.INS XBRL Instance -- opk-20180630 XML 3.05M
9: EX-101.CAL XBRL Calculations -- opk-20180630_cal XML 243K
10: EX-101.DEF XBRL Definitions -- opk-20180630_def XML 900K
11: EX-101.LAB XBRL Labels -- opk-20180630_lab XML 1.91M
12: EX-101.PRE XBRL Presentations -- opk-20180630_pre XML 1.15M
8: EX-101.SCH XBRL Schema -- opk-20180630 XSD 195K
77: ZIP XBRL Zipped Folder -- 0000944809-18-000035-xbrl Zip 296K
| Exhibit |
(1) | I have reviewed this Quarterly Report on Form 10-Q of OPKO Health, Inc.; |
(2) | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
(3) | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
(4) | The
registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
(a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries,
is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
(b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
(c) | Evaluated the effectiveness of the
registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
(d) | Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially
affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
(5) | The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
(a) | All
significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
(b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
Date:
August 7, 2018 | |
Chief Executive Officer | |
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 8/7/18 | 8-K | ||
| For Period end: | 6/30/18 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/18/21 Opko Health, Inc. 10-K 12/31/20 111:16M |